[go: up one dir, main page]

AU2001280889A1 - Molecular toxicology modeling - Google Patents

Molecular toxicology modeling

Info

Publication number
AU2001280889A1
AU2001280889A1 AU2001280889A AU8088901A AU2001280889A1 AU 2001280889 A1 AU2001280889 A1 AU 2001280889A1 AU 2001280889 A AU2001280889 A AU 2001280889A AU 8088901 A AU8088901 A AU 8088901A AU 2001280889 A1 AU2001280889 A1 AU 2001280889A1
Authority
AU
Australia
Prior art keywords
molecular toxicology
modeling
toxicology modeling
molecular
toxicology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280889A
Inventor
Arthur L. Castle
Michael R. Elashoff
Kory R. Johnson
Donna Mendrick
Mark W. Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ore Pharmaceuticals Inc
Original Assignee
Ore Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ore Pharmaceuticals Inc filed Critical Ore Pharmaceuticals Inc
Publication of AU2001280889A1 publication Critical patent/AU2001280889A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001280889A 2000-07-31 2001-07-30 Molecular toxicology modeling Abandoned AU2001280889A1 (en)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US22204000P 2000-07-31 2000-07-31
US60/222,040 2000-07-31
US24488000P 2000-11-02 2000-11-02
US60/244,880 2000-11-02
US29002901P 2001-05-11 2001-05-11
US60/290,029 2001-05-11
US29064501P 2001-05-15 2001-05-15
US60/290,645 2001-05-15
US29233601P 2001-05-22 2001-05-22
US60/292,336 2001-05-22
US29579801P 2001-06-06 2001-06-06
US60/295,798 2001-06-06
US29745701P 2001-06-13 2001-06-13
US60/297,457 2001-06-13
US29888401P 2001-06-19 2001-06-19
US60/298,884 2001-06-19
US30345901P 2001-07-09 2001-07-09
US60/303,459 2001-07-09
PCT/US2001/023872 WO2002010453A2 (en) 2000-07-31 2001-07-30 Molecular toxicology modeling

Publications (1)

Publication Number Publication Date
AU2001280889A1 true AU2001280889A1 (en) 2002-02-13

Family

ID=27578706

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280889A Abandoned AU2001280889A1 (en) 2000-07-31 2001-07-30 Molecular toxicology modeling

Country Status (6)

Country Link
US (2) US20020119462A1 (en)
EP (1) EP1364049A2 (en)
JP (2) JP2004522411A (en)
AU (1) AU2001280889A1 (en)
CA (1) CA2414421A1 (en)
WO (1) WO2002010453A2 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7921068B2 (en) * 1998-05-01 2011-04-05 Health Discovery Corporation Data mining platform for knowledge discovery from heterogeneous data types and/or heterogeneous data sources
US7444308B2 (en) * 2001-06-15 2008-10-28 Health Discovery Corporation Data mining platform for bioinformatics and other knowledge discovery
US7590493B2 (en) * 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
AU2002339829A1 (en) * 2001-05-22 2002-12-03 Gene Logic, Inc. Molecular toxicology modeling
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
AU2002304006A1 (en) * 2001-06-15 2003-01-02 Biowulf Technologies, Llc Data mining platform for bioinformatics and other knowledge discovery
US20040014040A1 (en) * 2001-07-10 2004-01-22 Donna Mendrick Cardiotoxin molecular toxicology modeling
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20070054269A1 (en) * 2001-07-10 2007-03-08 Mendrick Donna L Molecular cardiotoxicology modeling
US20050071088A1 (en) * 2001-08-13 2005-03-31 Landfield Philip W Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
WO2003042857A1 (en) * 2001-11-01 2003-05-22 Gene Network Sciences, Inc. Network ingerence methods
US20030194725A1 (en) * 2001-11-19 2003-10-16 Tsvika Greener Methods for identifying and validating potential drug targets
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
AU2003214981A1 (en) * 2002-01-31 2003-09-02 Gene Logic, Inc. Molecular hepatotoxicology modeling
WO2003078574A2 (en) * 2002-03-11 2003-09-25 Lipomics Technologies, Inc. Novel metabolic targets and markers
EP1344834A3 (en) * 2002-03-14 2004-06-02 F. Hoffmann-La Roche Ag Methods for the toxicity prediction of a compound
JP2003304888A (en) * 2002-03-14 2003-10-28 F Hoffmann La Roche Ag Methods for predicting the toxicity of compounds
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
WO2004037200A2 (en) * 2002-10-22 2004-05-06 Iconix Pharmaceuticals, Inc. Reticulocyte depletion signatures
US7778782B1 (en) 2002-12-17 2010-08-17 Entelos, Inc. Peroxisome proliferation activated receptor alpha (PPARα) signatures
US7396645B1 (en) 2002-12-17 2008-07-08 Entelos, Inc. Cholestasis signature
US7519519B1 (en) 2002-12-20 2009-04-14 Entelos, Inc. Signature projection score
US7422854B1 (en) 2002-12-20 2008-09-09 Entelos, Inc. Cholesterol reduction signature
AU2003288649A1 (en) * 2002-12-31 2004-07-22 Pharmacia & Upjohn Company Llc Canine cyp1a2 sequences
US7853406B2 (en) * 2003-06-13 2010-12-14 Entelos, Inc. Predictive toxicology for biological systems
WO2004114081A2 (en) * 2003-06-20 2004-12-29 Paradigm Genetics, Inc. Methods and systems for creation of a coherence database
WO2005014793A2 (en) * 2003-08-07 2005-02-17 Gene Logic, Inc. Primary rat hepatocyte toxicity modeling
US20070026406A1 (en) * 2003-08-13 2007-02-01 Iconix Pharmaceuticals, Inc. Apparatus and method for classifying multi-dimensional biological data
DE10342274B4 (en) * 2003-09-12 2007-11-15 Siemens Ag Identify pharmaceutical targets
DE10344345B3 (en) 2003-09-24 2005-05-12 Siemens Ag Method for communication in an ad hoc radio communication system
JP2007535305A (en) * 2003-11-24 2007-12-06 ジーン ロジック インコーポレイテッド Methods for molecular toxicity modeling
US20070218460A1 (en) * 2003-11-27 2007-09-20 Takeda Pharmaceutical Company Limited Method of Estimating Toxicity of Drug
US20080281526A1 (en) * 2004-03-22 2008-11-13 Diggans James C Methods For Molecular Toxicology Modeling
WO2005095649A1 (en) * 2004-03-31 2005-10-13 Genocheck Co. Ltd. Dna chip for screening of peroxisome proliferator
JP2007533005A (en) * 2004-04-07 2007-11-15 ジーン ロジック インコーポレイテッド Hepatotoxic molecular model
US20060035250A1 (en) * 2004-06-10 2006-02-16 Georges Natsoulis Necessary and sufficient reagent sets for chemogenomic analysis
US7588892B2 (en) * 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
WO2006008005A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 2 (hzf2)
US20060142233A1 (en) * 2004-11-09 2006-06-29 Ting-Kai Li Gene expression and genetic changes implicated in alcoholism
CN1920567B (en) * 2005-08-26 2012-01-04 中国科学院上海生命科学研究院 Application of hexulose (phosphokinase)
EP1767939A1 (en) * 2005-09-23 2007-03-28 F. Hoffmann-La Roche Ag FABP4 as marker for a toxic effect
US20070198653A1 (en) * 2005-12-30 2007-08-23 Kurt Jarnagin Systems and methods for remote computer-based analysis of user-provided chemogenomic data
US7467118B2 (en) 2006-01-12 2008-12-16 Entelos Inc. Adjusted sparse linear programming method for classifying multi-dimensional biological data
ES2300176B1 (en) * 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas METHOD FOR THE MOLECULAR PROSTATE CANCER DIAGNOSIS, KIT TO IMPLEMENT THE METHOD.
US11001881B2 (en) * 2006-08-24 2021-05-11 California Institute Of Technology Methods for detecting analytes
WO2008014485A2 (en) 2006-07-28 2008-01-31 California Institute Of Technology Multiplex q-pcr arrays
US11525156B2 (en) 2006-07-28 2022-12-13 California Institute Of Technology Multiplex Q-PCR arrays
US11560588B2 (en) 2006-08-24 2023-01-24 California Institute Of Technology Multiplex Q-PCR arrays
US20100021885A1 (en) * 2006-09-18 2010-01-28 Mark Fielden Reagent sets and gene signatures for non-genotoxic hepatocarcinogenicity
AU2008283794B2 (en) 2007-07-31 2014-03-20 Board Of Regents, The University Of Texas System Micro-RNAs that control myosin expression and myofiber identity
CA2751489A1 (en) 2009-02-04 2010-08-12 Board Of Regents, The University Of Texas System Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders
US20120034613A1 (en) * 2010-08-03 2012-02-09 Nse Products, Inc. Apparatus and Method for Testing Relationships Between Gene Expression and Physical Appearance of Skin
WO2013016226A1 (en) * 2011-07-22 2013-01-31 Metamark Genetics, Inc. Quality control method for digital pathology
JP6124498B2 (en) * 2011-07-29 2017-05-10 株式会社メディクローム Evaluation method of biotoxicity of chemical substances
CN102721814A (en) * 2011-11-16 2012-10-10 天津美德太平洋科技有限公司 F protein detection reagent and detection method therefor
US9846885B1 (en) * 2014-04-30 2017-12-19 Intuit Inc. Method and system for comparing commercial entities based on purchase patterns
ES2748117T3 (en) * 2015-04-22 2020-03-13 Euroimmun Medizinische Labordiagnostika Ag Diagnosis of a new autoimmune disease
JP2016104032A (en) * 2016-02-23 2016-06-09 株式会社メディクローム Evaluation method of chemical biotoxicity
WO2017155858A1 (en) 2016-03-07 2017-09-14 Insilixa, Inc. Nucleic acid sequence identification using solid-phase cyclic single base extension
JP7558167B2 (en) 2018-12-03 2024-09-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Oligobenzamide analogs and their use in cancer treatment - Patents.com
CN113924041B (en) 2019-03-14 2024-12-03 因斯利克萨公司 Method and system for fluorescence detection based on time gating

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE160178T1 (en) * 1993-01-21 1997-11-15 Harvard College METHODS AND DIAGNOSTIC KITS USING MAMMAL STRESS PROMOTORS FOR DETERMINING THE TOXICITY OF A COMPOUND
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6228589B1 (en) * 1996-10-11 2001-05-08 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
JP2001507675A (en) * 1996-11-04 2001-06-12 ３―ディメンショナル ファーマシューティカルズ インコーポレイテッド Systems, methods, and computer program products for identifying compounds having desired properties
US6165709A (en) * 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
WO1999010536A1 (en) * 1997-08-22 1999-03-04 Yale University A process to study changes in gene expression in granulocytic cells
US6403778B1 (en) * 1998-05-04 2002-06-11 Incyte Genomics, Inc. Toxicological response markers
US6132969A (en) * 1998-06-19 2000-10-17 Rosetta Inpharmatics, Inc. Methods for testing biological network models
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
EP1108067A2 (en) * 1998-08-28 2001-06-20 Incyte Pharmaceuticals, Inc. Toxicological response markers
US6160105A (en) * 1998-10-13 2000-12-12 Incyte Pharmaceuticals, Inc. Monitoring toxicological responses
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
KR20010080722A (en) * 1998-12-09 2001-08-22 추후제출 Toxicity typing using embryoid bodies
US6372431B1 (en) * 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
US20010049139A1 (en) * 2000-03-23 2001-12-06 Eric Lagasse Hepatic regeneration from hematopoietic stem cells
WO2002006537A2 (en) * 2000-07-13 2002-01-24 Curagen Corporation Methods of identifying renal protective factors
AU2002230997A1 (en) * 2000-12-15 2002-06-24 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
US6518330B2 (en) * 2001-02-13 2003-02-11 Board Of Trustees Of University Of Illinois Multifunctional autonomically healing composite material
US7993907B2 (en) * 2001-05-08 2011-08-09 Mowycal Lending, Llc Biochips and method of screening using drug induced gene and protein expression profiling
AU2002316146B2 (en) * 2001-05-15 2007-09-06 Psychogenics Inc. Systems and methods for monitoring behaviour informatics
US6956233B2 (en) * 2002-08-26 2005-10-18 Sin-Etsu Chemical Co., Ltd. Plated substrate for hard disk medium

Also Published As

Publication number Publication date
CA2414421A1 (en) 2002-02-07
US20020119462A1 (en) 2002-08-29
EP1364049A2 (en) 2003-11-26
JP2008148706A (en) 2008-07-03
WO2002010453A3 (en) 2003-08-14
JP2004522411A (en) 2004-07-29
WO2002010453A2 (en) 2002-02-07
US20080215250A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
AU2001280889A1 (en) Molecular toxicology modeling
AU2002339829A1 (en) Molecular toxicology modeling
AU2001260921A1 (en) Molecular imprinting
AU2001262847A1 (en) Language-understanding
AU2001280182A1 (en) Molded laminate
AU2000267458A1 (en) Hypercomputer
AU2001254546A1 (en) Aminopiperidines
AU2001220246A1 (en) Neckphone
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001258349A1 (en) Bisacylguanidine
AU2001279754A1 (en) Indoloquinazolinones
AU2001258924A1 (en) Microsatellite-aflp
AU2002365904A1 (en) Cardiotoxin molecular toxicology modeling
AUPQ901700A0 (en) Molecular markers
AU2001281921A1 (en) Bdellosomes
AU2001291876A1 (en) Triazolo-epothilones
AU2001246864A1 (en) Hypotensors
AU2001282644A1 (en) Case
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001284503A1 (en) Enzyme-mimicking polymers
EP1201403A3 (en) Electrofusible units
AU5090000A (en) Barriers
AU2001255129A1 (en) Molecular markers
AU2001260192A1 (en) Glycinamides
AU2001284173A1 (en) Calycins